Back Pain News and Research RSS Feed - Back Pain News and Research

Back pain is a very common problem affecting almost all individuals at some point in their lives. Back pain most commonly affects the lower back although it can be felt anywhere along the spine. An individual may experience aching, tension and stiffness that lasts for only a few days or weeks, or these symptoms may continue for many months or even years.

In most cases, back pain does not have a specific or serious cause and is often referred to as 'non-specific' pain. However, the pain can be triggered or worsened by, for example, a poor sitting or standing posture or bending or lifting incorrectly.

The use of painkillers and keeping active is often sufficient for the condition to resolve within 12 weeks. If back pain lasts longer than this, in which case it is termed chronic pain, an individual should visit their doctor. If the back pain is accompanied by any one of a fever, unexplained weight loss, swelling in the back, chest pain, leg pain, loss of bladder or bowel control, inability to pass urine, or pain that is worse at night, then medical help should be sought immediately. These are termed 'red flag symptoms' and could be a sign of something more serious such as rheumatoid arthritis, a slipped disc or osteoporosis.

People can reduce their chance of developing back pain by engaging in regular exercise, particularly swimming or walking, taking care to bend from the knees and hips rather than the back and maintaining a good posture.
NICE recommends FIRMAGON for treating advanced hormone-dependent prostate cancer in adults with spinal metastases

NICE recommends FIRMAGON for treating advanced hormone-dependent prostate cancer in adults with spinal metastases

The National Institute for Health and Care Excellence (NICE) today issued its Final Appraisal Determination (FAD) recommending FIRMAGON (degarelix) as an option for treating advanced hormone-dependent prostate cancer, only in adults with spinal metastases who present with signs or symptoms of spinal cord compression. [More]

FzioMed receives FDA notification to convene usage of Oxiplex Gel

FzioMed, Inc., a medical device manufacturer specializing in biomaterials, has received notification from FDA that the Medical Device Dispute Resolution Panel (MDDRP) will convene and make a decision on the approvability of Oxiplex Gel on June 10, 2014. [More]

Study shows spinal stimulation therapy may have potential to change prognosis of people with paralysis

Four people with paraplegia are able to voluntarily move previously paralyzed muscles as a result of a novel therapy that involves electrical stimulation of the spinal cord, according to a study funded in part by the National Institutes of Health and the Christopher & Dana Reeve Foundation. [More]

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE). [More]
Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas Pharma Inc. and Medivation Inc. today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI® (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated. [More]
Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C) compared to placebo in patients with high cholesterol. [More]
New ambitious Government scheme to help people return to work from sick leave

New ambitious Government scheme to help people return to work from sick leave

A REPORT from University of Huddersfield experts has ensured that an ambitious Government scheme to help more people return to work from sick leave will include telephone support as a key component. [More]
Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

Otsuka Pharmaceutical Co., Ltd. today announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Samsca (generic name: tolvaptan) has been approved in Japan in 7.5-mg and 15-mg tablet forms for extended use for the additional indication of ADPKD. Also, the new dosage form of 30-mg Samsca tablets has received approval for the indication of ADPKD. [More]
Elsevier launches Open Access, online-only journal Internet Interventions

Elsevier launches Open Access, online-only journal Internet Interventions

Elsevier, a world-leading provider of scientific, technical and medical (STM) information products and services, is pleased to announce the launch of the Open Access, online-only journal Internet Interventions. [More]
PhotoMedex Q4 2013 revenues up 16% to $63.5 million

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

PhotoMedex, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2013. [More]

Study suggests surgical treatment for herniated discs increases savings to society over long term

​Annually, more than 10 million people experience back pain in the United States. More than 200,000 of these patients undergo surgery to alleviate pain due to a herniated disc. [More]
Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. [More]
Mainstay Medical initiates clinical trial to investigate ReActiv8 as treatment for adults with CLBP

Mainstay Medical initiates clinical trial to investigate ReActiv8 as treatment for adults with CLBP

Mainstay Medical today announced that it has secured approval from Ethics Committees in Australia to start a clinical trial of ReActiv8, its innovative implantable neurostimulation device for the treatment of people with Chronic Low Back Pain (CLBP). Recruitment of subjects for the trial has commenced at three clinical sites in Australia. [More]
Minimally invasive surgery outcomes show favorable results in low back pain patients

Minimally invasive surgery outcomes show favorable results in low back pain patients

Beaumont research findings published in the February online issue of Spine shows that patients who have a low back surgery called minimally invasive transforaminal lumbar interbody fusion, end up better off in many ways than patients who have more invasive surgery to alleviate debilitating pain. [More]

Storytelling can help doctors recall opioid guidelines

In the fight against a nationwide prescription opioid abuse epidemic, Penn Medicine researchers are using storytelling to help doctors recall important, potentially lifesaving national guidelines on how to prescribe these medications. [More]

Study reveals spinal manipulation therapy reduces severity of pain in many patients

The lessening of pain sensitivity achieved with spinal manipulation therapy (SMT) occurs as a result of the treatment and not as much from a placebo effect caused by the expectation of receiving SMT, according to a study published in The Journal of Pain. [More]

Ways to help manage chronic pain

Musculoskeletal pain of the bone, joint and muscles is one of the most common reasons for primary care visits in the United States. According to a literature review appearing in a recent issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), chronic pain, or pain that persists beyond an expected period of healing, is estimated to affect 100 million Americans. [More]
Highlights: N.D. hospital and abortion docs; Calif. sugary beverage bill; aging home care workers in Texas

Highlights: N.D. hospital and abortion docs; Calif. sugary beverage bill; aging home care workers in Texas

A Democratic candidate who has explicitly defended Obamacare holds a slight lead in a special congressional election in Florida that both parties are eyeing as a test of the political impact of the healthcare law. A poll released Thursday by the Tampa Bay Times shows Democrat Alex Sink leading her Republican opponent, David Jolly, 42% to 35% among people considered likely to vote in the March 11 special election. [More]
Study reveals that more than 14% of pregnant women are prescribed opioids for pain

Study reveals that more than 14% of pregnant women are prescribed opioids for pain

More than 14 percent of pregnant women were prescribed opioids (narcotics) for pain at some time during their pregnancy, according to a study posted to the online version of Anesthesiology. [More]
Core stabilization exercise in stroke patients could be enhanced by real-time video feedback

Core stabilization exercise in stroke patients could be enhanced by real-time video feedback

About 80% of stroke survivors experience hemiparesis, which causes weakness or the inability to move one side of the body. Core stabilization exercise to improve postural stability and independent walking in chronic hemiparetic stroke patients could be enhanced by real-time video feedback, report researchers in Restorative Neurology and Neuroscience. [More]